top of page


A 2-Part Open-Label Phase I Study of TAVO412 in Patients with Advanced or Metastatic Solid Tumors who progressed on prior approved standard of care therapy

This medical study involves two parts and is looking at a new treatment called TAVO412. The study is open-label, meaning everyone knows what treatment they're getting. It's in Phase I, which is an early stage to test safety. They are studying patients with advanced or spreading solid tumors who haven't responded well to standard treatments that are already approved. The goal is to see if TAVO412 is safe and potentially helpful for these patients.

Advanced: Advanced cancer means that the cancer cells from the original tumor (primary tumor) get loose, spread by traveling through the body, and start a new tumor (metastatic tumor) somewhere else in the body.

For more information about the trial, click the link below:


Clinical Trial Site: Sinai

To see all available clinical trials click here.

Recent Posts

See All


A first-in-human, phase 1/2, open-label, multi-center, dose-escalation and dose-expansion study to evaluate safety, tolerability, pharmacokinetics, and anti-tumor activity of the ATR inhibitor IMP9064


A Multi-Cohort Exploratory Study of Neoadjuvant Cemiplimab for the Treatment of Resectable NSCLC, HCC, and HNSCC. Some patients have a tumor that is “resectable,” which means that it is able to be rem


Tislelizumab Consolidation after Liver-Directed Therapy for Hepatocellular Carcinoma (Phase II Study) This is a medical study to evaluate the safety and efficacy of tislelizumab in combination with ot

Bình luận

bottom of page